Five-year data from Novo Nordisk's late-stage trial that evaluated long-term treatment using Rebinyn, or nonacog beta pegol, or N9-GP, in previously treated pediatric patients with severe hemophilia B aged 12 years or younger, found the therapy to be safe and effective in treating and preventing spontaneous bleeds. Findings were reported in the journal Thrombosis and Haemostasis.
Long-term use of Rebinyn benefits children with severe hemophilia B
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.